Skip to main content

Table 1 Study eligibility criteria

From: Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial

Eligibility

Exclusion criteria

• Men or women 20–65 years of age

• Previous treatment with nifurtimox or benznidazole

• Positive serology for T. cruzi (at least two different techniques applied to the same blood sample) in the last 10 years

• Lack of compliance/tolerance to a 10-day run-in period

• No clinical suspicion, or active risk factors for, chronic cardiomyopathy

• Abnormal values in blood cell counts or laboratory tests for hepatic and renal function

• Negligible risk of vector T. cruzi re-infection

• Any medical/social condition hindering free participation

• Capable of complying with the planned study visits

• Current or planned pregnancy, or not using secure birth methods for women of childbearing age